title: Evaluation of the Efficacy of Solifenacin for Preventing Catheter-Related Bladder Discomfort After Transurethral Resection of Bladder Tumors in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective, Randomized, Multicenter Study.
abstract: Catheter-related bladder discomfort (CRBD) secondary to an indwelling urinary catheter is worse after transurethral resection of a bladder tumor (TUR-BT). We evaluated the incidence of CRBD and the efficacy of solifenacin for preventing CRBD after TUR-BT in patients with non-muscle invasive bladder cancer.
  
  
  
  In the present prospective, randomized, multicenter trial, we enrolled 148 patients with non-muscle invasive bladder cancer who underwent elective TUR-BT under general anesthesia. The patients were randomized to group S (n = 72) or group C (n = 76). The primary outcome was evaluable for 134 patients, who were included in the final analysis. Group S received solifenacin (5 mg orally) on the day before, the day, and the day after TUR-BT. The control group (group C) received standard care. CRBD was assessed at 1 and 2 hours postoperatively. Pain was assessed for 3 days starting 6 hours after TUR-BT using the visual analog scale.
  
  
  
  The incidence rates of CRBD in groups C and S were 72.2% and 64.5% at 1 hour and 68.1% and 53.2% at 2 hours, respectively. The incidence rates and severity of CRBD at 1 and 2 hours were not different between the 2 groups (P > .05 for both). The visual analog scale scores and the postoperative consumption of analgesics were not different between the 2 groups (P > .05 for both). None of the patients who received solifenacin experienced an adverse event.
  
  
  
  Pretreatment with solifenacin (5 mg) failed to decrease the incidence and severity of CRBD after TUR-BT.
authors.affiliation: Department of Urology, Pusan National University Yangsan Hospital, Yangsan, Korea.
authors.forename: Jae Min
authors.initials: JM
authors.lastname: Chung
authors.affiliation: Department of Urology, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
authors.forename: Hong Koo
authors.initials: HK
authors.lastname: Ha
authors.affiliation: Department of Anesthesiology and Pain Medicine, National Cancer Center, Goyang, Gyeonggi, Korea.
authors.forename: Dae Hyun
authors.initials: DH
authors.lastname: Kim
authors.affiliation: Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea.
authors.forename: Jungnam
authors.initials: J
authors.lastname: Joo
authors.affiliation: Biometric Research Branch, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea.
authors.forename: Sohee
authors.initials: S
authors.lastname: Kim
authors.affiliation: Department of Urology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Dong Wan
authors.initials: DW
authors.lastname: Sohn
authors.affiliation: Center for Prostate Cancer, National Cancer Center, Goyang, Gyeonggi, Korea.
authors.forename: Sung Han
authors.initials: SH
authors.lastname: Kim
authors.affiliation: Center for Prostate Cancer, National Cancer Center, Goyang, Gyeonggi, Korea. Electronic address: seohk@ncc.re.kr.
authors.forename: Ho Kyung
authors.initials: HK
authors.lastname: Seo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D012720:Severity of Illness Index; D000069464:Solifenacin Succinate / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000601:surgery*; D014546:Urinary Catheterization / Q000009:adverse effects*; D064804:Urological Agents / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D064804:Urological Agents; D000069464:Solifenacin Succinate
keywords: Anticholinergic drug; Pretreatment; Transurethral resection; Urinary catheters; Visual analog scale